Skip to main content

Advertisement

SpringerLink
Log in

Presence of Myofibroblasts and Expression of Matrix Metalloproteinase-2 (MMP-2) in Ameloblastomas Correlate with Rupture of the Osseous Cortical

  • Original Paper
  • Published:
Pathology & Oncology Research

Abstract

Myofibroblasts are frequent in the stroma of neoplasm and by the expression of proteinases they can influence tumor infiltration and progression. In the present study, presence of myofibroblasts and expression of matrix metalloproteinase-2 (MMP-2) and urokinase plasminogen activator (uPA) were examined in intra-osseous solid multicystic ameloblastomas to determine their roles in the clinicopathological features of the tumors. Fifty seven ameloblastomas were analyzed immunohistochemically with antibodies against the isoform α of the smooth muscle actin (α-SMA), a specific marker of myofibroblasts, MMP-2 and uPA. Myofibroblasts were found in the stroma, in close contact with neoplastic cell islands, of ~58% (n = 33) of the ameloblastomas. MMP-2 and uPA were found in the cytoplasm of both neoplastic and stromal cells. A significant correlation between presence of myofibroblasts and MMP-2 expression was observed. Abundant presence of myofibroblast in the stroma of the tumors and expression of MMP-2 in the neoplastic or stromal cells were significantly correlated with rupture of the osseous cortical, which has been considered an important prognostic marker of ameloblastoma aggressiveness. Ours results suggest that abundant presence of myofibroblasts and expression of MMP-2 in solid ameloblastomas may be associated with a more aggressive infiltrative behavior.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Desmouliere A, Chaponnier C, Gabbiani G (2005) Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13:7–12

    Article  PubMed  Google Scholar 

  2. Desmouliere A, Guyot C, Gabbiani G (2004) The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 48:509–517

    Article  PubMed  CAS  Google Scholar 

  3. Kuroda N, Shimasaki N, Miyazaki E et al. (2006) The distribution of myofibroblasts and CD34-positive stromal cells in normal renal pelvis and ureter and their cancers. Histol Histopathol 21:1303–1307

    PubMed  CAS  Google Scholar 

  4. Powell DW, Adegboyega PA, Di Mari JF et al. (2005) Epithelial cells and their neighbors I. Role of intestinal myofibroblasts in development, repair, and cancer. Am J Physiol Gastrointest Liver Physiol 289:G2–G7

    Article  PubMed  CAS  Google Scholar 

  5. Darby IA, Hewitson TD (2007) Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol 257:143–179

    Article  PubMed  CAS  Google Scholar 

  6. Bitu CC, Sobral LM, Kellermann MG et al. (2006) Heterogeneous presence of myofibroblasts in hereditary gingival fibromatosis. J Clin Periodontol 33:393–400

    Article  PubMed  CAS  Google Scholar 

  7. Gabbiani G (2003) The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 200:500–503

    Article  PubMed  CAS  Google Scholar 

  8. Kunz-Schughart LA, Knuechel R (2002) Tumor-associated fibroblasts (part II): Functional impact on tumor tissue. Histol Histopathol 17:623–637

    PubMed  CAS  Google Scholar 

  9. Kunz-Schughart LA, Knuechel R (2002) Tumor-associated fibroblasts (part I): Active stromal participants in tumor development and progression? Histol Histopathol 17:599–621

    PubMed  CAS  Google Scholar 

  10. Scotton CJ, Chambers RC (2007) Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 132:1311–1321

    Article  PubMed  Google Scholar 

  11. Mukaratirwa S, Koninkx JF, Gruys E et al. (2005) Mutual paracrine effects of colorectal tumour cells and stromal cells: modulation of tumour and stromal cell differentiation and extracellular matrix component production in culture. Int J Exp Pathol 86:219–229

    Article  PubMed  CAS  Google Scholar 

  12. Offersen BV, Nielsen BS, Hoyer-Hansen G et al. (2003) The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol 163:1887–1899

    PubMed  CAS  Google Scholar 

  13. Orimo A, Weinberg RA (2006) Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 5:1597–1601

    PubMed  CAS  Google Scholar 

  14. Helary C, Ovtracht L, Coulomb B et al. (2006) Dense fibrillar collagen matrices: a model to study myofibroblast behaviour during wound healing. Biomaterials 27:4443–4452

    Article  PubMed  CAS  Google Scholar 

  15. Soini Y, Satta J, Maatta M et al. (2001) Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart. J Pathol 194:225–231

    Article  PubMed  CAS  Google Scholar 

  16. Pender SL, MacDonald TT (2004) Matrix metalloproteinases and the gut - new roles for old enzymes. Curr Opin Pharmacol 4:546–550

    Article  PubMed  CAS  Google Scholar 

  17. Hatane T, Yoshida E, Kawano J et al. (1998) Prostaglandin I2 analog enhances the expression of urokinase-type plasminogen activator and wound healing in cultured human fibroblast. Biochim Biophys Acta 1403:189–198

    Article  PubMed  CAS  Google Scholar 

  18. Dubuisson L, Monvoisin A, Nielsen BS et al. (2000) Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. J Pathol 190:190–195

    Article  PubMed  CAS  Google Scholar 

  19. Monvoisin A, Neaud V, De Ledinghen V et al. (1999) Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase. J Hepatol 30:511–518

    Article  PubMed  CAS  Google Scholar 

  20. Plekhanova OS, Stepanova VV, Ratner EI (2006) Urokinase plasminogen activator in injured adventitia increases the number of myofibroblasts and augments early proliferation. J Vasc Res 43:437–446

    Article  PubMed  CAS  Google Scholar 

  21. Reichart PA, Philipsen HP, Sonner S (1995) Ameloblastoma: biological profile of 3677 cases. Eur J Cancer B Oral Oncol 31B:86–99

    Article  PubMed  CAS  Google Scholar 

  22. Kumamoto H, Ooya K (2006) Immunohistochemical detection of MT1-MMP, RECK, and EMMPRIN in ameloblastic tumors. J Oral Pathol Med 35:345–351

    Article  PubMed  CAS  Google Scholar 

  23. Kumamoto H, Ooya K (2007) Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors. J Oral Pathol Med 36:488–494

    PubMed  CAS  Google Scholar 

  24. Kumamoto H, Yamauchi K, Yoshida M et al. (2003) Immunohistochemical detection of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in ameloblastomas. J Oral Pathol Med 32:114–120

    Article  PubMed  CAS  Google Scholar 

  25. Pinheiro JJ, Freitas VM, Moretti AI et al (2004) Local invasiveness of ameloblastoma. Role played by matrix metalloproteinases and proliferative activity. Histopathology 45:65–72

    Article  PubMed  CAS  Google Scholar 

  26. Suh KS, Crutchley JM, Koochek A et al. (2007) Reciprocal modifications of CLIC4 in tumor epithelium and stroma mark malignant progression of multiple human cancers. Clin Cancer Res 13:121–131

    Article  PubMed  CAS  Google Scholar 

  27. Kellermann MG, Sobral LM, da Silva SD, Zecchin KG, Graner E, Lopes MA, Kowalski LP, Coletta RD (2008) Mutual paracrine effects of oral squamous cell carcinoma cells and normal oral fibroblasts: induction of fibroblast to myofibroblast transdifferentiation and modulation of tumor cell proliferation. Oral Oncol 4:509–517

    Article  Google Scholar 

  28. Mahadevan D, Von Hoff DD (2007) Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6:1186–1197

    Article  PubMed  CAS  Google Scholar 

  29. Casey TM, Eneman J, Crocker A et al (2007) Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-beta1) increase invasion rate of tumor cells: a population study. Breast Cancer Res Treat Aug 3. doi:10.1007/s10549-007-9684-7

  30. Kellermann MG, Sobral LM, da Silva SD et al. (2007) Myofibroblasts in the stroma of oral squamous cell carcinoma are associated with poor prognosis. Histopathology 51:849–853

    Article  PubMed  CAS  Google Scholar 

  31. Lewis MP, Lygoe KA, Nystrom ML et al. (2004) Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J Cancer 90:822–832

    Article  PubMed  CAS  Google Scholar 

  32. Chauhan H, Abraham A, Phillips JR et al. (2003) There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions. J Clin Pathol 56:271–276

    Article  PubMed  CAS  Google Scholar 

  33. Shimasaki N, Kuroda N, Miyazaki E et al. (2006) The distribution pattern of myofibroblasts in the stroma of human bladder carcinoma depends on their invasiveness. Histol Histopathol 21:349–353

    PubMed  CAS  Google Scholar 

  34. Takata T, Miyauchi M, Ogawa I et al. (2000) Immunoexpression of transforming growth factor beta in desmoplastic ameloblastoma. Virchows Arch 436:319–323

    Article  PubMed  CAS  Google Scholar 

  35. Smith SM, Bartov SA (1986) Ameloblastoma with myofibroblasts: first report. J Oral Pathol 15:284–286

    Article  PubMed  CAS  Google Scholar 

  36. Rothouse LS, Majack RA, Fay JT (1980) An ameloblastoma with myofibroblasts and intracellular septate junctions. Cancer 45:2858–2863

    Article  PubMed  CAS  Google Scholar 

  37. Lombardi T, Morgan PR (1995) Immunohistochemical characterisation of odontogenic cysts with mesenchymal and myofilament markers. J Oral Pathol Med 24:170–176

    Article  PubMed  CAS  Google Scholar 

  38. Vered M, Shohat I, Buchner A et al. (2005) Myofibroblasts in stroma of odontogenic cysts and tumors can contribute to variations in the biological behavior of lesions. Oral Oncol 41:1028–1033

    Article  PubMed  Google Scholar 

  39. Carlson ER, Marx RE (2006) The ameloblastoma: primary, curative surgical management. J Oral Maxillofac Surg 64:484–494

    Article  PubMed  Google Scholar 

  40. Ueno S, Mushimoto K, Shirasu R (1989) Prognostic evaluation of ameloblastoma based on histologic and radiographic typing. J Oral Maxillofac Surg 47:11–15

    Article  PubMed  CAS  Google Scholar 

  41. Sampson DE, Pogrel MA (1999) Management of mandibular ameloblastoma: the clinical basis for a treatment algorithm. J Oral Maxillofac Surg 57:1074–1077; discussion 78–9

    Article  PubMed  CAS  Google Scholar 

  42. McKaig BC, McWilliams D, Watson SA et al. (2003) Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 162:1355–1360

    PubMed  CAS  Google Scholar 

  43. Czochra P, Klopcic B, Meyer E et al. (2006) Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 45:419–428

    Article  PubMed  CAS  Google Scholar 

  44. Seomun Y, Kim J, Lee EH et al. (2001) Overexpression of matrix metalloproteinase-2 mediates phenotypic transformation of lens epithelial cells. Biochem J 358:41–48

    Article  PubMed  CAS  Google Scholar 

  45. Porter KE, Turner NA, O’Regan DJ et al. (2004) Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res 64:507–515

    Article  PubMed  CAS  Google Scholar 

  46. Deng X, He G, Levine A et al. (2008) Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer. Int J Cancer 122:209–218

    Article  PubMed  CAS  Google Scholar 

  47. Dass K, Ahmad A, Azmi AS et al. (2008) Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 34:122–136

    Article  PubMed  CAS  Google Scholar 

  48. Fisher JL, Mackie PS, Howard ML et al. (2001) The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. Clin Cancer Res 7:1654–1660

    PubMed  CAS  Google Scholar 

  49. Stillfried GE, Saunders DN, Ranson M (2007) Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res 9:R14

    Article  PubMed  Google Scholar 

  50. Nielsen BS, Rank F, Illemann M et al. (2007) Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int J Cancer 120:2086–2095

    Article  PubMed  CAS  Google Scholar 

  51. Ji F, Chen YL, Jin EY et al. (2005) Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer. World J Gastroenterol 11:3222–3226

    PubMed  CAS  Google Scholar 

  52. Bernstein AM, Twining SS, Warejcka DJ et al. (2007) Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation. Mol Biol Cell 18:2716–2727

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from Fundação de Amparo a Pesquisa do Estado de São Paulo-FAPESP, São Paulo, Brazil for RDC and FAV. E.R. Fregnani and L. M. Sobral is supported by Fundação de Amparo a Pesquisa do Estado de São Paulo-FAPESP, São Paulo, Brazil.

Author information

Authors and Affiliations

  1. Department of Stomatology, A. C. Camargo Cancer Hospital, R. Professor Antônio Prudente, 211 São Paulo-SP-Liberdade-CEP, 01509-010, São Paulo, Brazil

    Eduardo Rodrigues Fregnani & Fabio Abreu Alves

  2. Department of Oral Diagnosis, School of Dentistry, State University of Campinas, Piracicaba, São Paulo, Brazil

    Lays M. Sobral & Ricardo D. Coletta

  3. Department of Pathology, A. C. Camargo Cancer Hospital, São Paulo, Brazil

    Fernando Augusto Soares

  4. Department of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer Hospital, São Paulo, Brazil

    Luis Paulo Kowalski

Authors
  1. Eduardo Rodrigues Fregnani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lays M. Sobral
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fabio Abreu Alves
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fernando Augusto Soares
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luis Paulo Kowalski
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ricardo D. Coletta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eduardo Rodrigues Fregnani.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Table

Correlation of the bone cortical status and duration of the symptoms or tumor size in ameloblastomas (DOC 35.0 KB).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fregnani, E.R., Sobral, L.M., Alves, F.A. et al. Presence of Myofibroblasts and Expression of Matrix Metalloproteinase-2 (MMP-2) in Ameloblastomas Correlate with Rupture of the Osseous Cortical. Pathol. Oncol. Res. 15, 231–240 (2009). https://doi.org/10.1007/s12253-008-9110-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-008-9110-4

Keywords

Search

Navigation